Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of temozolomide with or without bevacizumab in recurrent grade II/III glioma
2009-017422-39Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab in glioma, astrocytoma, Oligodendroglioma (OG) and 1 more (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival at 12 months (OS12). Started Sep 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
gliomaastrocytomaOligodendroglioma (OG)oligoastrocytoma
Beyond the preview
Go deeper on 2009-017422-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017422-39.